Blue Book Archives

Tag: Blue Book

The definitive diagnosis and classification of individual cancers underpins the care of individual cancer patients, as well as research into cancer causation, prevention, diagnosis, and treatment. Traditionally, cancer classification has been based on consensus of histopathological opinion, with very limited consideration of molecular pathology. But new technologies are now transforming the field of pathology more rapidly than at any other time during the past 30 years, and it has become increasingly clear that the traditional approach to cancer classification is insufficient. Our understanding of cancer at a molecular level has now reached the point that this information must be included in diagnoses. Digital pathology and image analysis are also producing new insights, providing quantitative justification of many existing diagnostic criteria while challenging others. The rapid improvement in computer technology, including artificial intelligence, is already producing clinically applicable aids to diagnosis, and this trend is likely to accelerate.

There is an urgent need to integrate these facets of diagnosis into cancer classification internationally, and to update the WHO Classification of Tumours on a regular basis. IARC has been responsible for the WHO Classification of Tumours, also known as the WHO Blue Books, since the 3rd edition (2000–2005), which covered all organ sites in 10 volumes. The characteristics of each cancer type, including diagnostic criteria, pathological features, and associated molecular alterations, are described and illustrated in a strictly disease-oriented manner to provide the international standards for diagnosis and cancer research.

A spotlight on NENs, Awareness, Patient AdvocacyAdvanced neuroendocrine cancer, Blue Book, Carcinoid syndrome, Carcinoid tumour, Cushing's syndrome, Diagnosis, Ectopic Cushing’s syndrome (ECS), Gastrinoma, Gastro-entero-pancreatic neuroendocrine tumour (GEP-NET), Glucagonoma, Hormones, Incurable cancer, Insulinoma, Metastatic Neuroendocrine Cancer, Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN), NET syndromes, Neuroendocrine, Neuroendocrine cancer, Neuroendocrine carcinoma (NEC), Neuroendocrine neoplasm (NEN), Neuroendocrine tumour (NET), Somatostatinoma, VIPoma

Neuroendocrine Neoplasms: A riddle wrapped in a mystery inside an enigma

By Ronny Allan Feb 26, 2025 0 Comments

A spotlight on NENs - Types, Awareness, Patient AdvocacyBlue Book, Differentiation, Grading, High grade neuroendocrine neoplasm (NEN), High grade neuroendocrine tumour (NET), Ki-67, Large cell neuroendocrine carcinoma (LCNEC), MANEC, Merkel cell carcinoma, Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN), Molecular markers, Neuroendocrine carcinoma (NEC), Neuroendocrine neoplasm (NEN), Neuroendocrine tumour (NET), Poorly differentiated, Small cell lung cancer (SCLC), Small cell neuroendocrine carcinoma (SCNEC), Somatostatin receptors (SSTR), Well differentiated

A spotlight on Grade 3 (High grade) Neuroendocrine Neoplasms

By Ronny Allan Oct 03, 2024 5 Comments

Reviewed and updated 3rd Jan 2025 High Grade Neuroendocrine Neoplasms - the forgotten patient group? When reading articles in the mainstream media, found in medical publications; and even listening to doctors speak about my disease, it's clear that the focus is on the term "Neuroendocrine Tumours" or NET for short. Many websites of advocate foundation organisations and specialist scientific organisations, all still use the term "NET" in their naming. I too am guilty of having a large Facebook site falling into this category. It's little wonder that those with high grade disease can often feel like the forgotten patient group. …

Patient AdvocacyBlue Book, Cancer grading, Cancer staging, Carcinoid tumour, Differentiation, ENETS, Grade, High grade neuroendocrine tumour (NET), Intermediate grade NET, Ki-67, Large cell neuroendocrine carcinoma (LCNEC), Low Grade NETs, MEN1 syndrome, Mitotic count, Mitotic rate, Neuroendocrine cancer, Neuroendocrine carcinoma (NEC), Neuroendocrine tumour (NET), Pathology, Poorly differentiated, Proliferative rate, Small cell neuroendocrine carcinoma (SCNEC), Stage, Surgery, TNM staging system, Well differentiated

The Classification, Grading and Staging of Neuroendocrine Neoplasms (incorporating WHO 2022 classification changes)

By Ronny Allan Mar 11, 2024 25 Comments

- Updated 11th March 2024 - This section of my website has been published since 2015 but the most recent update to the World Health Organisation (WHO) Classification of Neuroendocrine Neoplasms is so significant, so gamechanging, that I have re-released the updated text. You may see these important publications called 'Blue Books'. Words are very important in Neuroendocrine Neoplasms (NENs). Nomenclature has important meaning and context more than most other cancers due to the heterogeneity of this group of neoplasms. Grade and Stage are two factors inextricably linked to the nomenclature and while there have been less changes in these…